Skip to main content

Table 1 Incidence of amenorrhea induced by the most commonly used chemotherapy regimens in breast cancer

From: Cancer and fertility preservation: fertility preservation in breast cancer patients

       Rate of amenorrhea
Reference Year Patients (n) Chemotherapy regimen Duration of treatment (months) Follow-up to definite amenorrhea (months) Percentage Age (years)
Goldhirsch and colleagues [4] 1990 541 CMF 1 9 14/34 <40/>40
   387   6   33/81 <40/>40
Bines and colleagues [5] 1996 3,628 CMF 3 to 24 12 40/76 <40/>40
Levine and colleagues [6] 1998 359 CMF 6 NA 42.6  
   132 FEC 6    
Goodwin and colleagues [7] 1999 83 CMF 6 12 55.6  
   25 FEC 6   64.6  
Nabholtz and colleagues [8] 2002 745 ACD 6 33 51.4  
   746 FAC 6    
Fornier and colleagues [9] 2005 84 AC-T/D 6 12 13  
   82 AC-T/D + tamoxifen    17  
Martin and colleagues [10] 2005 420 ACD 6 NA 61.7  
   403 FAC    52.4  
Venturini and colleagues [11] 2005 503 FEC 4 120 64  
Petrek and colleagues [12] 2006 120 AC 4 36 53  
   168 ACT 6   42  
   83 CMF 8   82  
   38 FAC 6   NA  
   34 FACT 6   NA  
   19 ACD 6   45  
Tham and colleagues [13] 2007 75 AC 4 12 44/81 <40/>40
   116 AC + T/D 4 + 3   61/85 <40/>40
Total   8,681      
  1. AC, adriamycin (doxorubicin), and cyclophosphamide; ACD, adriamycin (doxurubicin), cyclophosphamide and docetaxel; AC-T/D, adriamycin (doxorubicin), cyclophosphamide and taxol (paclitaxel)/docetaxel; CMF, cyclophosphamide, methotrexate, and 5-fluorouracil; FAC, 5-fluorouracil, adriamycin (doxorubicin), and cyclophosphamide; FACT, 5-fluorouracil, adriamycin (doxorubicin), cyclophosphamide and taxol (paclitaxel); FEC, 5-fluorouracil, epirubicin, and cyclophosphamide; NA, not available.